Antiplatelet therapies: Platelet GPIIb/IIIa antagonists and beyond

K. Konstantopoulos, S. A. Mousa

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Accumulating evidence supports the critical role of platelet involvement in arterial thrombosis, and argues for the development of more efficacious, yet safe, antiplatelet therapies. Aspirin continues to be used routinely for the management of acute myocardial infarction, unstable angina and secondary prevention of ischemic events. Nevertheless, adverse clinical outcomes still occur. Newer-generation drugs such as clopidogrel (an adenosine-diphosphate receptor antagonist) and intravenous glycoprotein (GP)IIb/IIIa antagonists (inhibitors of platelet aggregation irrespective of the stimulus) have demonstrated significant clinical benefit. This review will discuss the role of the aforementioned antiplatelet therapies in thrombotic disorders as well as future directions in the field.

Original languageEnglish (US)
Pages (from-to)1086-1092
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Issue number8
StatePublished - Sep 4 2001
Externally publishedYes


  • Antiplatelet agents
  • GPIIb/IIIa antagonists
  • Thrombosis

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Antiplatelet therapies: Platelet GPIIb/IIIa antagonists and beyond'. Together they form a unique fingerprint.

Cite this